Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab

Hypereosinophilic syndrome (HES) is characterized by a persistently elevated eosinophil count associated with eosinophil-related end-organ damage and thromboembolic events, in the absence of an identifiable cause. We present a case of idiopathic HES with evidence of peripheral and tissue eosinophili...

Full description

Bibliographic Details
Main Authors:	Dana Kay, Ali Ataya, Xiuli Liu, Jena Auerbach, Dan Urbine
Format:	Article
Language:	English
Published:	Elsevier 2018-01-01
Series:	Respiratory Medicine Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213007118301084

id	doaj-10d297f4d2864c6f83d39c848e22a9bf
record_format	Article
spelling	doaj-10d297f4d2864c6f83d39c848e22a9bf2020-11-25T01:01:28ZengElsevierRespiratory Medicine Case Reports2213-00712018-01-01253032Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with MepolizumabDana Kay0Ali Ataya1Xiuli Liu2Jena Auerbach3Dan Urbine4Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USA; Corresponding author. Department of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 1600 SW Archer Rd, M452, PO Box 100225, Gainesville, FL 32610, USA.Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USADepartment of Pathology, University of Florida, Gainesville, FL, USADepartment of Pathology, University of Florida, Gainesville, FL, USADivision of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USAHypereosinophilic syndrome (HES) is characterized by a persistently elevated eosinophil count associated with eosinophil-related end-organ damage and thromboembolic events, in the absence of an identifiable cause. We present a case of idiopathic HES with evidence of peripheral and tissue eosinophilia while on high dose prednisone, associated with muscle tension dysphonia, colitis, and jackhammer esophagus. The patient was treated with the interleukin-5 inhibitor, Mepolizumab, with resolution of symptoms including dyspnea, diarrhea and dysphonia.http://www.sciencedirect.com/science/article/pii/S2213007118301084
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Dana Kay Ali Ataya Xiuli Liu Jena Auerbach Dan Urbine
spellingShingle	Dana Kay Ali Ataya Xiuli Liu Jena Auerbach Dan Urbine Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab Respiratory Medicine Case Reports
author_facet	Dana Kay Ali Ataya Xiuli Liu Jena Auerbach Dan Urbine
author_sort	Dana Kay
title	Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
title_short	Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
title_full	Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
title_fullStr	Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
title_full_unstemmed	Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
title_sort	dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with mepolizumab
publisher	Elsevier
series	Respiratory Medicine Case Reports
issn	2213-0071
publishDate	2018-01-01
description	Hypereosinophilic syndrome (HES) is characterized by a persistently elevated eosinophil count associated with eosinophil-related end-organ damage and thromboembolic events, in the absence of an identifiable cause. We present a case of idiopathic HES with evidence of peripheral and tissue eosinophilia while on high dose prednisone, associated with muscle tension dysphonia, colitis, and jackhammer esophagus. The patient was treated with the interleukin-5 inhibitor, Mepolizumab, with resolution of symptoms including dyspnea, diarrhea and dysphonia.
url	http://www.sciencedirect.com/science/article/pii/S2213007118301084
work_keys_str_mv	AT danakay dysphoniaanddyspneainidiopathichypereosinophilicsyndrometreatedwithmepolizumab AT aliataya dysphoniaanddyspneainidiopathichypereosinophilicsyndrometreatedwithmepolizumab AT xiuliliu dysphoniaanddyspneainidiopathichypereosinophilicsyndrometreatedwithmepolizumab AT jenaauerbach dysphoniaanddyspneainidiopathichypereosinophilicsyndrometreatedwithmepolizumab AT danurbine dysphoniaanddyspneainidiopathichypereosinophilicsyndrometreatedwithmepolizumab
_version_	1725209311882248192

Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab

Similar Items